StockData

Fulcrum Therapeutics vs Kura Oncology

FULC and KURA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How FULC and KURA compare

Kura Oncology is the larger company, worth 2.3 times as much as Fulcrum Therapeutics ($666M against $286M).

Fulcrum Therapeutics scores higher on the StockData Score (8 against 1 for Kura Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricFULCKURA
Size and price
Market cap$286M$666M
Share price$3.75$7.49
Change, 1 year−56.6%−33.2%
Change, 5 years−75.1%−46.5%
Beta (5Y)1.362.30
Employees55260
StockData Score
Total score8 (better)1
Valuation score1 (better)0
Growth score00
Performance score1 (better)0
Health score6 (better)1
Dividend score00
Valuation
P/S–8.4×
P/B0.9× (better)37.1×
FCF yield−23.1%−13.4% (better)
Profitability
Operating margin–−394%
Net margin–−369%
FCF margin–−112%
Return on equity−32.4% (better)−225%
Return on invested capital−35.0%–
Financial health
Debt / equity0.000.55 (better)
Interest coverage–−227.1×
Current ratio31.35 (better)3.60
Altman Z-score10.37 (better)−3.56
Piotroski F-score3 (better)1
Dividends and buybacks
Buyback yield−1.5%–
Shareholder yield−1.5%0.00% (better)
Ownership
Held by institutions112%98.0%
Held by insiders34.7%2.7%
Insider net buying, 12 months−$57.5M$512K (better)
Short interest, % of float12.9%14.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.